Fobancort

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fobancort

Fobancort: Foundational Overview

Property Description
Active ingredient Betamethasone Dipropionate, Fusidic Acid
Form Cream, Ointment
Pharmacological class Steroidal Antibiotic Combination
Common use Inflammatory skin conditions with bacterial contamination
Origin Synthetic (Corticosteroid), Derived (Antibiotic)

What Type of Medicine is Fobancort?

Fobancort is a prescription-only topical medication classified as a steroidal antibiotic combination, which utilizes two distinct active components in a single product. It is a fixed-dose combination product, a strategy clinically recognized for its ability to enhance patient compliance by reducing the number of applications compared to using two separate agents. The high-level pharmacological class is defined by its two primary actions: anti-inflammatory from the corticosteroid and antibacterial from the antibiotic. Its use represents a specific intervention for skin conditions where inflammation and bacterial presence must be addressed concurrently.

What is Fobancort's Composition and Physical Form?

The two active ingredients [INN] responsible for Fobancort's dual action are Betamethasone Dipropionate and Fusidic Acid. The medication is intended solely for topical administration, typically supplied in dosage forms such as a cream or ointment, utilizing an emollient base to facilitate application. Betamethasone Dipropionate belongs to a potent class of topical corticosteroids, which means it has a significant effect in reducing skin inflammation. Fusidic Acid functions as an antibacterial agent, recognized for its ability to inhibit bacterial protein synthesis which is crucial for controlling microbial proliferation.

What is the General Purpose of This Combination Drug?

The general purpose of Fobancort is to provide comprehensive relief and stabilization for inflammatory skin conditions—such as eczematous dermatoses—that are either suspected or confirmed to have developed a secondary bacterial infection. This combination is beneficial because it enables the simultaneous addressing of both the intense inflammatory symptoms (like redness, swelling, and itching) and the active bacterial contamination. This targeted approach is applied in scenarios where treating one component without the other would compromise the overall recovery of the affected skin.

What side effects are possible with Fobancort?

Possible Side Effects and Safety Information

The safety profile for Fobancort (Betamethasone Dipropionate/Fusidic Acid) is based on classifications from official regulatory documents and centers on two main areas: local skin reactions and systemic risks from the corticosteroid component. The adverse reactions are officially classified according to frequency.


Adverse Reactions and Frequency

Adverse effects are grouped by affected body systems. Reactions affecting the Skin and subcutaneous tissue disorders and General disorders at the application site are most commonly documented.

Classification Examples of Documented Reactions
Uncommon Skin burning sensation, pruritus (itching), hypersensitivity reactions, contact dermatitis.
Rare Erythema (redness), urticaria (hives), rash.
Not Known Blurred vision, Glaucoma, Cataract, Topical Steroid Withdrawal reactions.

Systemic Risk and Exposure Patterns

The most serious documented safety concerns relate to systemic absorption of the potent Betamethasone component. This rare potential risk involves the Endocrine system disorders, specifically the risk of Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and features of Cushing’s syndrome.

These systemic adverse effects, along with local reactions such as skin atrophy, are officially noted to be more likely with prolonged use, application to large surface areas, or use under occlusion. Furthermore, there is a documented risk of Topical Steroid Withdrawal reactions following the abrupt discontinuation of prolonged therapy.

Population-Specific Safety: Pediatric patients are officially noted to have a greater susceptibility to these systemic effects. The use of the Fusidic Acid component also carries a regulatory restriction concerning the potential for developing bacterial resistance with extended or recurrent use.

Overdose and Emergency Response

The official regulatory profile for Fobancort overdose focuses on the risks associated with the Betamethasone Dipropionate component following prolonged use or excessive topical application.

Documented Manifestations and Risks

Excessive systemic absorption of the corticosteroid may lead to suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis. Documented overdose presentations include features of Hypercortisolism (Cushing’s syndrome), such as Moon face, central obesity, and weight gain, along with metabolic signs like Hyperglycaemia and Glucosuria. Serious outcomes may involve Adrenocortical insufficiency or steroid withdrawal crisis.

Paediatric patients are identified as a population with greater susceptibility to HPA-axis suppression due to their increased skin surface area to body weight ratio. For the Fusidic Acid component, official documentation notes that systemic toxicity is considered unlikely from topical application, and no specific overdose information is available.

Emergency Actions and Management

Regulatory information dictates that users must seek emergency medical attention or contact a doctor immediately if a large amount of the medication has been accidentally swallowed. Urgent medical assistance may be required even in the absence of immediate symptoms.

Treatment for overdose is officially described as symptomatic and supportive. There is no specific antidote known for the effects of either active substance. Management protocols require the assessment of HPA-axis function, often via tests like the ACTH stimulation test, and necessitate the gradual withdrawal of the drug.

Therapeutic Uses of Fobancort

Fobancort is commonly used in situations involving certain distressing symptoms related to inflammatory or irritative states that are complicated by bacterial infection.

Managing Inflammatory Skin Conditions with Secondary Infection

Fobancort is commonly used across conditions characterized by periods of heightened symptoms, such as various forms of eczematous dermatoses—including atopic, discoid, stasis, contact, and seborrhoeic eczema—when secondary bacterial infection is confirmed or suspected. It is considered relevant in clinical settings that involve acute or unstable symptom patterns, which generally include redness, swelling, and severe itching, alongside signs of bacterial contamination like oozing and crusting. This approach is applied across domains where additional symptomatic support is needed.


Targeting Acute Dual Symptom Clusters

The medication helps address symptom clusters that may become intense or disruptive, specifically where symptoms related to physical discomfort (like intense itching and inflammation) occur together with signs of bacterial activity. The combination is applied in addressing symptomatic discomfort stemming from both inflammatory and bacterial processes, which contributes to improved comfort and assists with supporting comfort when these symptoms interfere with routine activities. It is applied during phases when symptoms become more noticeable, offering symptomatic relief that may help patients cope more steadily with symptom fluctuations.

“This medication is applied in settings where symptoms create noticeable physiological strain due to the combined presence of inflammation and infection.”


Quick Fact: Symptom Management

The combination is used to manage symptomatic discomfort when symptoms related to physical discomfort and bacterial contamination occur together, supporting the patient during difficult episodes by easing distress.


Eligibility and Restrictions for Use

Who Can and Cannot Use Fobancort?

Fobancort (Betamethasone Dipropionate/Fusidic Acid) is subject to strict eligibility rules defined by regulatory authorities to manage risks associated with its potent corticosteroid component.

Absolute Contraindications

The medicine must not be used in several populations and conditions. This includes infants under one year of age. Use is strictly prohibited for patients with skin conditions caused primarily by viruses (such as Herpes simplex or Varicella), fungi, or mycobacteria. Contraindications also extend to specific facial dermatoses, including rosacea, perioral dermatitis, acne vulgaris, and cutaneous ulcers, or known hypersensitivity to any ingredient.

Conditional Use and Restrictions

  • Children and Adolescents: While eligible from six years of age, use in children requires special caution; extensive application or prolonged treatment must be avoided.
  • Pregnancy: Use is generally not recommended unless necessary and the benefit outweighs potential risks.
  • Lactation: Permitted, but the medication must not be applied to the breast area.
  • Application Site: Use near the eyes requires special care to prevent ocular complications.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Fobancort is a topical medication, and due to its minimal systemic absorption under normal usage conditions, the risk of systemic drug-drug interactions is generally considered low by regulatory authorities. For most co-administered medicinal products, no formal interaction studies have been performed or are required.

However, the systemic properties of the active ingredient Fusidic Acid necessitate formal warnings concerning a specific, high-risk interaction that is required to be documented in product labeling.


Documented Exposure-Altering Interactions

Risk of Increased Exposure for Statins

The most significant documented interaction risk involves certain HMG-CoA Reductase Inhibitors (Statins), particularly those metabolized by the CYP3A4 enzyme system, such as Simvastatin and Atorvastatin. The Fusidic Acid component is a known inhibitor of both the CYP3A4 metabolic pathway and drug transporters (OATP1B1, BCRP).

This inhibition may lead to a reduced clearance and significantly increased plasma concentrations of the co-administered Statins. Consequently, this combination is classified in many regulatory contexts as contraindicated or requires mandatory interruption of the Statins due to the documented risk of severe muscular toxicity, including Rhabdomyolysis.


Other Interaction Contexts

Context Regulatory Statement
Timing-based separation No mandatory time separation rules are formally documented in the prescribing information.
Food, Alcohol, Supplements No specific interactions with food, alcohol, or herbal products are formally documented.

Mechanism of Action

How Fobancort Works: Mechanism of Action

Fobancort initiates its action by functioning as a synthetic agonist for the cytoplasmic Glucocorticoid Receptor ( GR). Upon binding, the activated drug-receptor complex translocates into the cell nucleus.

Within the nucleus, the primary mechanism is transcriptional repression, specifically achieved by inhibiting key pro-inflammatory transcription factors, such as NF-kappa B. This action limits the genetic transcription of inflammatory mediators, including cytokines, chemokines, and COX-2 enzymes, thereby suppressing the molecular steps that drive increased inflammatory signaling.

The resulting physiological consequence is the systemic modulation of immune function across both the innate and adaptive immune systems. This broad pathway interference decreases inflammatory mediator release and limits the function and migration of immune cells (leukocytes), leading to the physiological outcomes of inhibition of fluid accumulation and a decrease in local tissue immune activity. The GR's influence also extends to metabolic processes.

Dosage and Administration Information

How to Use Fobancort

Fobancort, a prescription-only combination of Betamethasone Dipropionate and Fusidic Acid, is administered strictly through the topical route, consistent with its formulation as a cream or ointment. Its use is governed by highly specific, time-limited instructions established to ensure appropriate administration.


Official Administration Guidelines

The standard protocol for the use of this fixed-dose combination requires the application of a small quantity applied thinly to the affected skin area. This application is scheduled to occur twice daily. The treatment is designed to be a short-course intervention; a single treatment course must not normally exceed 14 days (2 weeks). This duration limit is set to manage the risk of developing antimicrobial resistance and minimize exposure to the potent corticosteroid component.


Usage Constraints and Special Conditions

Usage instructions define constraints related to application site and patient population:

  • Pediatric Use: The medication is indicated for adults and children over 1 year of age. Its use in pediatric patients mandates special care, requiring the avoidance of large amounts, occlusion, and prolonged treatment.
  • Site Limitations: Application must be avoided in the proximity of the eyes. Prolonged use on the face is also restricted.
  • Procedural Detail: For lesions that are more resistant to treatment, the effect may be enhanced by occlusion (such as with polyethylene film), provided these occlusive methods are applied as directed and are not used in pediatric patients.

These official rules collectively structure the use of Fobancort as a controlled, high-potency, short-term topical therapy, with administration constraints centered on limiting both duration and site of exposure.

Recent Clinical Evidence

Research evidence / Overview of studies for Fobancort

Evidence for Use in Inflammatory Skin Conditions with Secondary Bacterial Contamination

Research examined Fobancort primarily through short-term Randomized Controlled Trials (RCTs) and systematic reviews. These RCTs are a key study type used in research exploring how symptoms change over time and are relevant in trials assessing short-term or episodic symptom patterns. These studies was studied for populations of adults and some children who had inflammatory conditions, like eczema, that were either confirmed or suspected to have a concurrent bacterial infection. Researchers monitored several key factors, including measurements of overall disease severity using standardized clinical scales, and outcomes related to physical discomfort such as redness and itching. They also examined the presence of bacteria on the skin to see if there were changes in the microbial load.

Compared to a non-medicated cream (the vehicle control), short-term trials focused on measuring differences in clinical composite scores related to the combined inflammatory and bacterial elements. Research describes patterns observed in the studies over the typical treatment duration of one to two weeks. The evidence quality for this context is described as high in published scientific reviews, though research provides limited information for long-term outcomes.


Comparison of Fobancort with Other Treatments

Research has also examined comparisons of Fobancort with other treatment approaches for infected inflammatory skin conditions. This involved RCTs that either compared the combination to a topical corticosteroid used alone (monotherapy) or to other available topical steroid/antibiotic combinations. This type of research is applied in studies examining patient-reported experiences against alternative care.

When was observed in studies against the steroid-only monotherapy, research monitored patterns related to the research focus when adding the antibiotic for bacterial contamination. When observed in studies comparing Fobancort to other fixed-dose combinations, research explored whether findings differed between the products on certain measured outcomes describing episodic or acute changes. The evidence from these comparisons generally contributes to understanding symptom patterns but does not always show a definitive difference in all measured outcomes.


Research Gaps and What Remains Uncertain

Scientific literature highlights several areas where certainty remains low or where more research is needed. Long-term effects are not fully established regarding disease recurrence or sustained effect. Existing studies do not provide sufficient insight to determine whether the antibiotic component is necessary for inflammation that is not confirmed or suspected to have a secondary bacterial infection. Evidence shows the combination was studied for situations where both inflammation and bacterial contamination were present.

Key Studies & References

  1. Fusidic Acid (DrugBank DB00898)

Frequently Asked Questions (FAQ)

Common questions about Fobancort (FAQ)


Q: How quickly does Fobancort usually start to work?

A: Official product information describes Fobancort as a short-term treatment. Clinical trial data suggests that changes in skin condition were monitored over the short duration of the studies, which often lasted one to two weeks.


Q: Can Fobancort be taken with common pain relievers like ibuprofen?

A: Fobancort is a topical medicine, and regulatory documents state that the risk of interactions with systemically administered products, such as oral pain relievers like ibuprofen, is considered minimal due to the low absorption into the bloodstream. No formal interaction studies involving Fobancort and common pain relievers have been performed.


Q: Do I need to change my diet while taking Fobancort?

A: According to the official product information, there are no specific interactions with food that have been formally documented. You can generally maintain your normal diet while using this topical medicine.


Q: Is it okay to drink coffee or tea when taking Fobancort?

A: Official prescribing information states that no specific interactions with coffee or tea have been formally documented for Fobancort.


Q: Does Fobancort cause hair loss?

A: Hair loss is not listed among the commonly reported local side effects of the topical medicine. However, some systemic side effects associated with the corticosteroid component, such as abnormal hair growth or thinning scalp hair, have been reported in medical literature related to widespread or prolonged use.


Q: Are there any long-term health risks associated with Fobancort?

A: Regulatory warnings emphasize that long-term, continuous topical therapy with Fobancort is generally advised against. Risks documented and linked to prolonged use include skin thinning (atrophy), HPA axis suppression (affecting natural hormone regulation), and the potential for the bacteria to develop resistance to the antibiotic component.


Q: Can people with high blood pressure use Fobancort?

A: High blood pressure (hypertension) has been documented as a potential systemic side effect of the corticosteroid component. This is considered a potential risk if significant amounts of the medicine are absorbed into the body, which is more likely with prolonged or extensive application.


Q: Is Fobancort considered a narcotic or habit-forming medicine?

A: Fobancort is a prescription medication classified as a combination of an antibiotic and a topical corticosteroid. It is not categorized by major regulatory authorities as a narcotic or controlled substance with a potential for abuse or habit formation.


Q: Why does the packaging say to avoid alcohol with Fobancort?

A: Formal prescribing information states that no specific interactions with alcohol are formally documented. Concerns about alcohol consumption while using Fobancort are best clarified through discussion with a healthcare provider.


Q: Are there any specific supplements that should not be taken with Fobancort?

A: Official documentation states that no specific interactions with herbal products or supplements have been formally documented for Fobancort due to its minimal absorption into the bloodstream.


Q: Does Fobancort interact with birth control pills?

A: Formal product information states that no interaction studies have been performed. Due to the minimal systemic absorption of the topical cream, Fobancort is not known to cause medically significant drug interactions with systemic products like birth control pills at recommended topical doses.


Q: What is the difference between Fobancort and similar over-the-counter medicines?

A: Fobancort is a prescription-only medicine because it contains two strong active components: a potent topical corticosteroid for inflammation and an antibacterial agent. This combination is intended for specific skin conditions that require a treatment level beyond what is typically available over-the-counter.


Q: Can Fobancort make me feel tired or drowsy?

A: Unusual or extreme tiredness has been reported as a potential systemic side effect associated with the corticosteroid component. This is considered a rare risk that could occur if significant systemic absorption of the medicine happens, such as from applying it to large areas or for long periods.


Q: Does Fobancort affect sleep patterns?

A: Difficulty falling asleep has been documented as a potential systemic side effect of the corticosteroid component in some cases. The possibility of this risk is related to the systemic absorption of the medicine.


Q: Can Fobancort be split or crushed?

A: Fobancort is supplied as a cream or ointment intended only for application to the skin. The concepts of splitting or crushing only apply to solid oral medications and are not relevant to this topical formulation.


Q: Does Fobancort cause weight gain or weight loss?

A: Weight gain is associated with the rare systemic risk known as Cushing's syndrome, which is a documented risk of the potent corticosteroid component. This risk is primarily a concern if the medicine is used for prolonged periods or over very large areas of the body.


Q: Why is Fobancort restricted for use in people with kidney disease?

A: The components of Fobancort, once systemically absorbed, are primarily excreted from the body by the kidneys. While the topical formulation is minimally absorbed, this excretion pathway means that kidney function is generally a consideration in the systemic use of similar medicines.


Q: Is there a generic version of Fobancort available?

A: Fobancort contains the active ingredients Betamethasone Dipropionate and Fusidic Acid. Combination products containing these same active ingredients may be available in generic or different branded versions, depending on the country.


Q: How does Fobancort differ from other drugs in its class?

A: Fobancort is a fixed-dose combination product that is specifically defined by its dual components: a potent corticosteroid (Betamethasone Dipropionate) for inflammation and an antibiotic (Fusidic Acid) for bacterial contamination.


Q: Are there different strengths or forms of Fobancort?

A: Yes, Fobancort is typically supplied in two primary forms, a cream and an ointment. These different physical forms usually contain the same percentages of the two active ingredients.


Q: Can Fobancort interact with herbal remedies like St. John's Wort?

A: Official prescribing information states that no specific interactions with herbal products, including St. John's Wort, have been formally documented.


Q: Is Fobancort a preventative or a treatment medicine?

A: Fobancort is defined as a treatment medicine. Its general purpose is to provide relief for existing inflammatory skin conditions that are already confirmed or suspected to have a secondary bacterial infection.


Q: Is Fobancort safe to take while breastfeeding?

A: Use is permitted during lactation according to regulatory documents. However, application to the breast area is to be avoided to prevent accidental ingestion by the infant.


Q: Does Fobancort need to be taken with food?

A: Fobancort is a topical medication applied directly to the skin, not an oral medicine. Its use is not dependent on food intake.


Q: Are headaches a common side effect of Fobancort?

A: Headache has been documented as a systemic side effect associated with the corticosteroid component. Like other systemic risks, this is considered a potential side effect if significant amounts of the medicine are absorbed into the body.


Q: Does Fobancort affect blood sugar levels?

A: The systemic absorption of the corticosteroid component has the potential to produce high blood sugar (hyperglycemia) and sugar in the urine (glucosuria) in certain patients, especially those who may be predisposed to elevated blood sugar.


Q: Is Fobancort commonly used in combination with other drugs?

A: Fobancort itself is a fixed-dose combination product, meaning it already contains two active ingredients (a corticosteroid and an antibiotic) that are used together as a single treatment for both inflammation and bacterial contamination.


Q: Does taking Fobancort affect lab tests?

A: Official product information states that the effect of Fobancort on standard laboratory tests has not been established.


Q: Does Fobancort lose its effect over time?

A: Official warnings mention that with extended or repeated use of the antibiotic component, there is a risk that the target bacteria may develop resistance. This resistance could potentially reduce the medicine’s ability to treat the bacterial infection effectively.


Q: Does Fobancort have a potential for abuse?

A: Fobancort is an antibiotic/corticosteroid combination product and is not categorized as a controlled substance by major regulatory authorities, meaning it does not have a recognized potential for abuse.

How should Fobancort be stored and disposed of?

Storage Conditions

Fobancort must be stored in alignment with official regulatory requirements to preserve its stability. The product must be stored at a temperature not above 30 C and should be protected from strong light.

Container Integrity and Stability

To prevent contamination and maintain product quality, the container must be kept well closed. The regulatory shelf-life for the unopened product is typically 36 months. Once the tube has been opened, the cream must be discarded within 6 months.

Child Safety and Disposal

As a mandatory safety precaution for all medicines, Fobancort must be stored out of the sight and reach of children.

For disposal, any unused medicinal product or waste material should be disposed of in accordance with local requirements, following pharmaceutical waste protocols instead of household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fobancort found in:

A-Z Index: